VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS)(www.appliedneurosolutions.com), a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer’s disease (AD), today reported that a peer-reviewed paper, “Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment,” will be published in an upcoming print edition of Neurobiology of Aging and is currently available to subscribers on the publication’s web site. The paper describes a longitudinal evaluation in the transition from mild cognitive impairment (MCI) to AD using five different cerebrospinal fluid (CSF) markers. The APNS P-Tau 231 biomarker was the strongest predictor of the decline from MCI to AD.
